FGFR1 and neoplasm: While the phase II study EAY131 led by Gong and colleagues, which enrolled 18 patients with tumor FGFR 1-4 amplification to receive erdafitinib and included 9 patients with BC did not meet its primary endpoint, with only one patient with FGFR1-amplified BC showing prolonged survival (101).